696602-10-5

Upstream product

• 99154-06-0 (E)-4-(3-hydroxyprop-1-enyl)benzonitrile 
• 90923-70-9 4-(1-hydroxy-allyl)benzonitrile 

Downstream Products

• 38276-71-0 3'-(p-Cyanophenyl)-allyl-4-methylphenylether 
• 38276-83-4 2-(1'-(p-Cyanophenyl)-allyl)-4-methylphenol 
• 1443128-89-9 tert-butyl (E)-5-(4-cyanophenyl)-2-diazopent-4-enoate 
• 1443129-01-8 tert-butyl (1S,2S,3R)-2-(4-cyanophenyl)bicyclo[1.1.0]butane-1-carboxylate 
• 1443129-39-2 C₁₈H₂₁NO₃ 
• 1433413-54-7 (E)-4-(3-(perfluorophenyl)prop-1-en-1-yl)benzonitrile 
• 1433413-62-7 C₁₆H₈F₅N 

Relevant academic research and scientific papers

Copper-Catalyzed Enantioselective Allylic Alkylation with a γ-Butyrolactone-Derived Silyl Ketene Acetal

Herein, we report a Cu-catalyzed enantioselective allylic alkylation using a γ-butyrolactone-derived silyl ketene acetal. Critical to the development of this work was the identification of a novel mono-picolinamide ligand with the appropriate steric and electronic properties to afford the desired products in high yield (up to 96 %) and high ee (up to 95 %). Aryl, aliphatic, and unsubstituted allylic chlorides bearing a broad range of functionality are well-tolerated. Spectroscopic studies reveal that a CuI species is likely the active catalyst, and DFT calculations suggest ligand sterics play an important role in determining Cu coordination and thus catalyst geometry.

One-pot formation of allylic chlorides from carbonyl derivatives

(Chemical Equation Presented) An efficient, one-pot method for the conversion of carbonyl electrophiles to allylic chlorides has been developed, by activating magnesium alkoxides in situ using TiCl4.

Factor xa inhibitors with aryl-amidines and derivatives, and prodrugs thereof

The present invention relates to a compound with aryl-amidines, particularly amidinoaryl-cyclopropanes, amidinoarylmethyl-pyrroles, amidinoaryl-benzenes, amidinoaryl-pyridines, or amindonoaryl-alanines, represented by formula (1), a pharmaceutically acceptable salt, a prodrug, a hydrate, a solvate or an isomer thereof, which are inhibitors of coagulation enzyme, factor Xa (FXa). The present invention also relates to a pharmaceutical composition containing the compound, and a method of using the same as an anticoagulant agent for treatment and prevention of thrombosis disorders.

Cyclic imino derivatives and pharmaceutical compositions containing them

The invention relates to cyclic imino compounds which have, inter alia, valuable pharmacological properties, especially inhibitory effects on cell aggregation, pharmaceutical compositions which contain these compounds and processes for preparing them.